SCHEMBL4315080

SCHEMBL4315080

Cc1ccsc1C(=O)Nc1cc(N2CCN(S(C)(=O)=O)CC2)ccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.59
AURKB Q96GD4 2/20 0.59
RAB9A P51151 6/20 0.38
NPC1 O15118 4/20 0.38
ALDH1A1 P00352 4/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 6/20 0.37
LMNA P02545 3/20 0.37
HPGD P15428 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 7/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
THRB P10828 1/20 0.36
KDM4E B2RXH2 3/20 0.36
USP2 O75604 2/20 0.36
HSD17B10 Q99714 2/20 0.36
GFER P55789 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4315086 1.00 AURKA (0.59) AURKAAURKBRAB9ANPC1ALDH1A1
SCHEMBL4314913 0.92 AURKA (0.58) AURKAAURKBRAB9ANPC1SMN1; SMN2
SCHEMBL4314905 0.92 AURKA (0.58) AURKAAURKBRAB9ANPC1SMN1; SMN2
SCHEMBL5265469 0.89 AURKA (0.60) AURKAAURKBRAB9ANPC1ALDH1A1
SCHEMBL4320733 0.89 AURKA (0.60) AURKAAURKBRAB9ANPC1ALDH1A1
SCHEMBL4320741 0.89 AURKA (0.60) AURKAAURKBRAB9ANPC1ALDH1A1
SCHEMBL4326955 0.89 AURKA (0.58) AURKAAURKBRAB9ANPC1SMN1; SMN2
SCHEMBL4326949 0.89 AURKA (0.58) AURKAAURKBRAB9ANPC1SMN1; SMN2
SCHEMBL4321140 0.88 AURKA (0.74) AURKAAURKBRAB9ANPC1SMN1; SMN2
SCHEMBL4315170 0.88 AURKA (0.61) AURKAAURKBRAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885RAB9A 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.